Maha Sai Lab plans to set up Active Pharmaceutical Ingredients in Telangana

Maha Sai Laboratories is planning a new Active Pharmaceutical Ingredients (API) project at Gummadidala, Hyderabad, Telangana, as an expansion of their existing facility. The Project cost is 43 Crores.The project is still in the planning stage, but the company has already acquired land for the site and is in the process of obtaining the necessary approvals. 

The company expects to start construction on the project in early 2024 and to commission it by the end of 2025. The new plant will produce a range of APIs, including antibiotics, anti-inflammatories, and cardiovascular drugs. Maha Sai Laboratories plans to export a significant portion of the production from the plant to its global markets. 

The expansion project is a part of Maha Sai Laboratories' strategy to strengthen its presence in the API market. The company is also planning to expand its capacity for other pharmaceutical products, such as formulations and finished dosage forms. The project is expected to have a positive impact on the Indian pharmaceutical industry. 

It will create jobs and boost the local economy. The project will also help to reduce India's dependence on imported APIs. Additionally, the project is expected to benefit Maha Sai Laboratories by helping it to expand its product portfolio and increase its market share.

As of September 2023, The project is now in the stage of receiving approvals & has obtained all necessary government permissions work of the project is anticipated to occur in either 2023 or 2024.

News by Rahul Yeligetti